Other biologically primarily based restrictions of EpiSign analysis is usually highlighted because of the four inconclusive samples within the clinical testing cohort. The present BAFopathy episignature is qualified on positive cases with pathogenic variants in ARID1B, ARID1A, SMARCB1, SMARCA2, and SMARCA4.17 consequently, it can be not possible to